6 results
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
20 Oct 23
Current report (foreign)
2:56pm
and nomination of women directors. Though the Board recognizes the importance of a reasonable degree of gender balance, at the present stage … of the Company's existence and development, it is imperative that the directors of the Company be the best candidates available, irrespective of gender.
b
F-3
EX-4.3
IPA
ImmunoPrecise Antibodies Ltd
10 Jul 23
Shelf registration (foreign)
7:04pm
to this Indenture as a whole and not to any particular Article, Section or other subdivision;
(4) "or" is not exclusive;
(5) words implying any gender shall apply
6-K
EX-99.2
IPA
ImmunoPrecise Antibodies Ltd
17 Nov 22
Current report (foreign)
9:36am
. Though the Board recognizes the importance of a reasonable degree of gender balance, at the present stage of the Company's existence and development … , it is imperative that the directors of the Company be the best candidates available, irrespective of gender.
b) If an issuer has adopted a policy
6-K
EX-99.2
IPA
ImmunoPrecise Antibodies Ltd
14 Apr 22
Current report (foreign)
10:18am
NAMED HEREIN
TABLE OF CONTENTS
INTERPRETATION
1.1
Definitions
1.2
Gender
1.3
Headings
1.4
Currency
1.5
Severability
1.6
Entire Agreement … and https://www.biostrand.be/en/ operated by the Operating Corporations as part of the Business.
1.2 Gender
Any reference in this Agreement to any
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
12 Nov 21
Current report (foreign)
8:58am
and nomination of women directors. Though the Board recognizes the importance of a reasonable degree of gender balance, at the present stage of the Company’s … existence and development, it is imperative that the directors of the Company be the best candidates available, irrespective of gender.
If an issuer
40FR12B
EX-99.27
ojo768djh h5
16 Sep 20
Initial registration of securities (Canada)
4:06pm
- Prev
- 1
- Next